<DOC>
	<DOCNO>NCT01277172</DOCNO>
	<brief_summary>This prospective international , multi-center , randomize , double-blind control study design ass compare pharmacokinetics , pharmacodynamics safety PBO-326 ( Rituximab ) Mabthera ( Rituximab ) combination CHOP previously untreated patient diffuse B cell Non Hodgkin lymphoma .</brief_summary>
	<brief_title>TREatment degeNerative Neoplastic Diseases With Rituximab</brief_title>
	<detailed_description>At present R-CHOP ( Rituximab plus Cyclofosfamide , Doxorrubicine , Vincristine Prednisone ) become standard care patient B cell Non Hodgkin Lymphoma CD20+ . Study perform pharmacodynamic ( PD ) pharmacokinetic ( PK ) measurment novel Rituximab comparison Mabthera evaluate safety metabolic well immunologic . Study protocolo design provide data impact treatment interchange study drug ( PBO-326 Mabthera ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Newly diagnose subject confirm pathologic diagnosis diffuse large B cell nonHodgkin 's lymphoma ( DLBCL ) base 2008 World Health Organization classification . 2 . CD20+ lymphoma cell screen . 3 . &gt; 18 year age screening . 4 . Ann Arbor Stages IIV screening . 5 . Any IPI score screening . 6 . Easten Cooperative Oncology Group ( ECOG ) performance status ( 02 ) Karnofsky scale &gt; 60 screening . 7 . Left ventricular ejection fraction &gt; 50 % . 8 . Willing able provide write informed consent prior perform study procedure . 9 . Women childbearing potential must use effective contraceptive method start screen 12 month follow last infusion . 1 . Hodgkin lymphoma . 2 . Any lymphoma CD20+ Diffuse Large B Cell Lymphoma ( DLBCL ) . 3 . Immunodeficiency syndrome Human immunodeficiency virus ( HIV ) seropositivity . 4 . Active uncontrolled infection ( viral , bacterial fungal infection ) require systemic therapy screen and/or baseline visit . 5 . Function Liver test &gt; 2 x upper normal value . 6 . Positive Hepatitis B surface antigen antibody Hepatitis C. 7 . Any serious active disease comorbid medical condition . 8 . Subjects , accord investigator , likely noncompliant uncooperative study . 9 . Pregnant breastfeed woman woman intend get pregnant study within 12 month follow last infusion . 10 . Treatment investigational drug within 90 day day 1 study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Rituximab</keyword>
	<keyword>LymphomaLymphoma</keyword>
	<keyword>Non-HodgkinLymphoma</keyword>
	<keyword>B-CellLymphoma</keyword>
	<keyword>Large B-Cell</keyword>
	<keyword>Disorders Lymphatic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Adverse Effects</keyword>
</DOC>